Anavex Life Sciences (AVXL)
2.46
-0.08 (3.15%)
Upcoming Events
Latest Headlines
Form 8-K ANAVEX LIFE SCIENCES For: May 20
May 22, 2026 8:16 AM - SEC Filing
Anavex receives NASDAQ delinquency notice for late quarterly filing
May 22, 2026 8:02 AM - StreetInsider
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
May 22, 2026 8:00 AM - StreetInsider
Form 8-K ANAVEX LIFE SCIENCES For: May 11
May 15, 2026 4:21 PM - SEC Filing
Form 3 ANAVEX LIFE SCIENCES For: May 04 Filed by: Kellmeyer Terrie
May 14, 2026 4:16 PM - SEC Filing
Form NT 10-Q ANAVEX LIFE SCIENCES For: Mar 31
May 11, 2026 4:31 PM - SEC Filing
Form 8-K ANAVEX LIFE SCIENCES For: Apr 30
May 6, 2026 7:05 AM - SEC Filing
Anavex names Terrie Kellmeyer interim CEO after Missling departure
May 6, 2026 7:00 AM - StreetInsider
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
May 6, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Starts Anavex Life Sciences (AVXL) at Buy
May 4, 2026 6:32 AM - StreetInsider
Form 3 ANAVEX LIFE SCIENCES For: Feb 23 Filed by: Paeger Axel
May 1, 2026 7:19 PM - SEC Filing
Anavex highlights research linking autism and Alzheimer's disease
April 14, 2026 7:32 AM - StreetInsider
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
April 14, 2026 7:30 AM - Globe NewsWire
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026 12:02 PM - Globe NewsWire
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026 7:30 AM - StreetInsider
Anavex withdraws EU marketing application for Alzheimer's drug
March 30, 2026 7:31 AM - StreetInsider
Anavex Life Sciences Provides Comprehensive Regulatory Update
March 30, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G/A ANAVEX LIFE SCIENCES Filed by: VANGUARD GROUP INC
March 26, 2026 3:49 PM - SEC Filing
Form 8-K ANAVEX LIFE SCIENCES For: Mar 25
March 25, 2026 4:07 PM - SEC Filing
Anavex withdraws EU marketing application for alzheimer's drug
March 25, 2026 7:30 AM - StreetInsider
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
March 25, 2026 7:30 AM - StreetInsider
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservat
March 23, 2026 7:30 AM - StreetInsider
Anavex cites study supporting autophagy failure theory in Alzheimer's
March 20, 2026 7:30 AM - StreetInsider
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
March 20, 2026 7:30 AM - StreetInsider
Anavex Life Sciences reports blarcamesine study results in Parkinson's model
March 17, 2026 7:30 AM - StreetInsider
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
March 17, 2026 7:30 AM - StreetInsider
Full Article List
